Austin, TX 11/2/2007 10:31:12 PM
Speak with other shareholders about: (Nasdaq: AMED), (OTCBB: CYCR), (Nasdaq: ACTS), (OTCBB: SYBD).
Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the “Chat Live” button at the top.
----------------------------------------------------------
Chat real-time with other investors about this AMED news release, by
clicking this link: http://www.stockwire.com/AMED
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=AMED
Amedisys, Inc. (Nasdaq: AMED) Current Price (42.49).
BATON ROUGE, La., Oct 30-- Amedisys, Inc. (Nasdaq: AMED - News; "Amedisys" or "the Company"), one of America's leading home health nursing companies, today reported its financial results for the third quarter ended September 30, 2007:"Our third quarter results were very strong, as we set record revenue and earnings," said William F. Borne, Chief Executive Officer of Amedisys. "Our strategic objective is to be the leading provider of high-quality, low-cost home health services in the market. Our results show that we are succeeding in our objective by continuing to grow both our home health and hospice businesses. With our recently announced $100 million unsecured revolving credit agreement, $250 million shelf registration and over $70 million in cash, we have expanded our financial flexibility to take advantage of future growth opportunities through acquisitions and de novo start-ups." Amedisys, Inc. provides home health and hospice services in the United States. Its home health services include nursing services, such as infusion therapy, skilled monitoring, assessments, and patient education; practical nursing services, including performance of technical procedures, administration of medications, and changing of surgical and medical dressings; and physical and occupational therapy. The company's home health services also comprise speech pathology and therapy to restore communication and oral skills; social work to help families address the problems associated with acute and chronic illnesses; home health aide services; and private duty services, such as continuous hourly nursing care and sitter services. It provides hospice services to patients using an interdisciplinary care team comprising a physician, a patient care manager, registered nurses, certified home health aides, social workers, a chaplain, a homemaker, and specially trained volunteers to assess the clinical, psychosocial, and spiritual needs of the patients and their families and manage that care accordingly. As of April 4, 2007, the company operated 261 Medicare-certified home health agencies and 14 Medicare-certified hospice agencies in 19 states. Amedisys was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
----------------------------------------------------------
Chat real-time with other investors about this CYCR news release, by
clicking this link: http://www.stockwire.com/CYCR
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=CYCR
CytoCore Inc. (OTCBB: CYCR) Current Price (0.34).
CHICAGO--Oct. 31--CytoCore, Inc. (OTCBB: CYCR) announced the selection of BVK as its advertising and public relations agency of record. CytoCore, a biopharmaceutical research and medical device company focused on early detection and treatment of reproductive-tract cancers, will work with BVK on an imminent product launch. Together, the two companies will devise brand positioning and product pipelines to fit the needs of multiple audiences. CytoCore, Inc., a life sciences company, designs, develops, and commercializes the screening systems to assist in the early detection of cancer. The company is focusing on the e2 cervical cell collection device, and the design and development of its various cancer screening systems for cancer and cancer-related diseases. It is developing InPath System to provide a noninvasive screening test for the detection of endometrial and uterine cancer and to enhance the cervical cancer screening process performed in laboratories. InPath System is a combination of protein antibodies, such as the Cocktail-CVX, and Cocktail-GCI and others, which allow the system to detect and highlight abnormal cancerous cells. It includes the e2 Collector, an approved sample collection device to replace the spatula and brush used to collect patient cytology samples; the Automated Image Proteomic System or AIPS workstation image analysis for automated slide screening of the P2X7 genetic biomarker from cytological and histological specimens; and a drug delivery system consisting of an applicator handle, which is the further development of e2 Collector handle, and drug-delivery modality in the form of a patch that provides a timed release of a therapeutic agent directly to the surface of the cervix. The company's products would be used in laboratory, clinic, or doctor's office. CytoCore was formerly known as Molecular Diagnostics, Inc. and changed its name to CytoCore, Inc. in 2006. The company is headquartered in Chicago, Illinois.
----------------------------------------------------------
Chat real-time with other investors about this ACTS news release, by
clicking this link: http://www.stockwire.com/ACTS
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=ACTS
Actions Semiconductor Co., Ltd. (Nasdaq: ACTS) Current Price (5.00).
ZHUHAI, China, Oct. 30 -- Actions Semiconductor Co., Ltd. (Nasdaq: ACTS), one of China's leading fabless semiconductor companies, today announced that Patricia Chou, Vice President of Finance, has been promoted to the position of chief financial officer as David Lee assumes the role of chairman of the board as part of the company's succession plan. In addition, the Board appointed Nan-Horng Yeh and Fred Chen as directors. Actions Semiconductor is one of China's leading fabless semiconductor companies that provides mixed-signal and multimedia SoC solutions for portable consumer electronics. Actions Semiconductor products include SoCs, firmware, software, solution development kits, as well as detailed specifications of other required components and the providers of those components. Actions Semiconductor also provides total product and technology solutions that allow customers to quickly introduce new portable consumer electronics to the mass market in a cost effective way. The company is headquartered in Zhuhai, China, with offices in Beijing and Shenzhen.
----------------------------------------------------------
Chat real-time with other investors about this SYBD news release, by
clicking this link: http://www.stockwire.com/SYBD
To view in-depth research, click the following link:
http://www.stockwire.com/detailed/analysis.php?company=SYBD
Synthetic Blood International, Inc (OTCBB: SYBD) Current Price (0.10).
COSTA MESA, Calif.--Oct 31--Synthetic Blood International, Inc. (OTCBB: SYBD) today announced that the PBS television series WIRED Science will explore research on perfluorocarbon-based molecules to create blood substitutes and will feature Oxycyte. The episode titled, "Blood Simple," will premiere Wednesday, October 31 at 8:00 p.m. Pacific time (for other time zones check your local listings). Oxycyte is Synthetic Blood's proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute. Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a blood substitute, a liquid ventilation product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for perfluorocarbons, and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes.
----------------------------------------------------------
As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.
As the saying goes...follow the money!
To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE RESEARCH GROUP INC..
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com, which is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. We intend to sell these shares at any given time.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
